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Disseminated non-tuberculous mycobacterium (dNTM) infection is rare in humans without human
immunodeﬁciency virus (HIV) infection. Previous reports have shown autoantibodies to human
interferon-gamma (IFN-g), which play important roles in mycobacterium infection, in the sera of patients
with non-HIV dNTM disease. Herein, we describe a 53-year-old male who was strongly suspected to have
multicentric Castleman disease (MCD) based on bone marrow study and chest radiological ﬁndings.
However, Mycobacterium kansasii was detected in respiratory samples including pleural effusion. We
initiated anti-mycobacterial therapy under intensive care; he died on the 48th hospital day. We detected
no hematological disorders, ruling out MCD postmortem. However, we detected M. kansasii in pulmo-
nary, liver, spleen and bone marrow tissues. Moreover, anti-IFN-g autoantibody was detected with strong
neutralizing capacity for IFN-g. We consider our present report to contribute to understanding of the
relationship between anti-IFN-g autoantibody and disease development.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Non-tuberculous mycobacteria (NTM) are environmental acid-
fast bacilli (AFB) commonly found worldwide. NTM usually cause
infections of pulmonary bronchi (pulmonary NTM; pNTM).1 Over
90% of pNTM disease is caused by Mycobacterium avium complex
(MAC), about 5% by Mycobacterium kansasii. In immunocompent
patients, pNTM disease is usually limited to the bronchi and lungs,
but patients with human immunodeﬁciency virus (HIV) infection
may progress to systemic disseminated disease.2 Disseminatede and Cardiac Care, Nippon
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-NC-ND license.NTM (dNTM) disease is regarded as a sign of acquired immuno-
deﬁciency syndrome (AIDS) due to HIV infection, whereas dNTM
diseasewithout HIV infection is very rare. Recently, the existence of
autoantibodies against interferon-gamma (IFN-g) has been shown
to be closely related to dNTM disease without HIV infection.3e5
A few reports on dNTM disease without HIV infection noted the
existence of anti-IFN-g autoantibody with strong neutralizing
capacity.5 We describe herein our dNTM patient who was HIV
negative but was infectedwithM. kansasii. This patient did not have
MAC infection but anti-IFN-g autoantibody, with strong neutral-
izing capacity, was detected.2. Case report
2.1. Patient proﬁle and clinical course
A 53-year-old male was referred to our hospital because of
dyspnea, decreased hemoglobin, and white blood cell (WBC)
counts over 30,000/mL. He was admitted and his laboratory
data and radiological ﬁndings were evaluated. Clinical laboratory
data on admission conﬁrmed high WBC counts and decreased
hemoglobin. A high serum total immunoglobulin-G level was also
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phatase and globulins and a low level of serum albumin. No serum
M protein was detected. Serum C-reactive protein was elevated,
indicating an inﬂammatory reaction. Soluble interleukin-2
receptor (sIL-2R) was elevated to 11,470 U/ml. Both anti-HIV and
anti-human T-cell leukemia virus (HTLV) antibody were negative.
Radiological ﬁndings on admission showed non-segmental and
patchy consolidation along bronchi in the bilateral lung paren-
chyma. Multiple mediastinal lymph nodes were enlarged
(Fig. 1AeC).
We initially suspected an abnormality of hematopoietic organs
and thus evaluated his bone marrow. The specimens revealed mild
hyperplasia with markedly increased atypical plasma cells. Several
further studies, including ﬂowcytometric analysis, were conducted
to assess whether the abnormal cells showed any signs of malig-
nancy. However, these atypical cells were ultimately determined to
represent benign reactive changes. To further evaluate the medi-
astinal lymphadenopathy, transbronchial aspiration cytology using
endobronchial ultrasonography was performed, but no signiﬁcant
ﬁndings were obtained. Based on polyclonal hypergammmopathy
by serology and plasma cells collected for the bone marrow anal-
ysis, MCD was highly suspected. To conﬁrm this diagnosis, surgical
biopsy specimens of mediastinal lymph nodes and the lung
parenchyma sample were obtained on the 31st hospital day.
However, a pulmonary specimen was obtained only from the right
lung, and adequate mediastinal lymph node specimens could not
be collected due to severe adhesion.Fig. 1. (A) Chest roentgenography (CR) and (B) and (C): thoracic computed tomography (TCT
showed non-segmental consolidation along bronchi with bronchovascular septal thickeninAfter surgical biopsy, we initiated tocilizumab and steroid
administration, because his general condition was deteriorating.
However, AFB were detected in a bronchial lavage specimen ob-
tained before surgical biopsy and pleural effusion collected at
surgical biopsy. The organismwas shown to beM. kansasii by DNAe
DNA hybridization methods. We immediately began isoniazid,
rifampicin and ethambutol treatment. However, despite these anti-
tuberculous agents, his condition continued to deteriorate. On the
40th hospital day, his laboratory data showed ongoing dissemi-
nated intravascular coagulaton and multiple organ failure. An
anticoagulant agent and continuous hemodiaﬁltration were star-
ted. Despite intensive care, he died on the 48th hospital day.
With permission from his family, a postmortem anatomical
evaluation was performed.M. kansasiiwas detected in tissues from
the lungs, liver, spleen and bone marrow, as well as blood cultures
(on the 44th, 45th and 46th hospital days).
2.2. Detection and neutralizing capacity of anti-IFN-g autoantibody
To assess the binding avidity of immunoglobulins to IFN-g, we
assayed anti-IFN-g autoantibody with an antigen capture assay by
ELISA. Brieﬂy, serum from the present patient, other serum samples
from patients with pNTM disease or pulmonary tuberculosis, and
from healthy controls were each diluted 2000-fold with 0.1%
bovine serum albumin/0.1% Tween-T/phosphate buffered saline
(PBS). A 50 mL volume of diluted serum was applied to a 96-well
transparent ﬂat-bottom plate (Nunc, Roskilde, Denmark) coated) ﬁndings on 1st hospital day. CR showed consolidation in bilateral lung ﬁelds and TCT
g and bulky mediastinal lymphadenopathy.
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Minneapolis, MN, US) after blocking with adequate agents. The
plate was kept at room temperature for 60 min. After washing,
autoantibodies captured by rhIFN-g were detected by peroxidase-
labeled anti-human Fab autoantibody (Santa Cruz, CA, US). After
washing, color was developed using tetramethylbenzidine (TMB).
Anti-IFN-g autoantibody was detected only in diluted serum
derived from the patient’s blood (Fig. 2A).
Inhibition binding activity for IFN-g was assayed using an IFN-g
assay ELISA plate (R&D systems). Brieﬂy, the same samples as those
used for the antigen capture assays were diluted 1,000-fold with
0.1% BSA/0.1% Tween-T/PBS containing 100 pg/mL rhIFN-g and
incubated at 37 C for 1 h. A 50 mL volume of the incubated sample
was applied to the IFN-g assay plate, for measurement according to
themanufacturer’s instructions. TMB developmentwas inhibited in
an incubated sample containing only the patient’s serum (Fig. 2B).
Neutralizing activity was measured as in previous reports.5,6
Brieﬂy, one million peripheral blood mononuclear cells (PBMNCs)
in a total of 1 mL of complete medium (10% fetal calf serum/RPMI
1640) were stimulated with LPS (200 ng) and IFN-g (1000 IU/mL)
in the presence of 100 mL of normal control serum, the pNTM
patient’s serum, or our patient’s serum (ﬁnal volume 1.1 mL), for
48 h at 37 C in 5%CO2. All added sera were the same as those used
for the antigen capture assays. Supernatants were harvested and
frozen at 20 C until the TNF-a and IL-10 measurements by
Quantikine (R&D systems) plate ELISA. Production of TNF-a was
inhibited in the patient’s serum, whereas IL-10 production was not
(Fig. 2C and D).Fig. 2. (A) Antigen capture assays of immunoglobulins against IFN-g in our patient’s serum
a pulmonary NTM (pNTM) patient’s serum (3rd lane from the left), and normal control (NC
recombinant human (rh) IFN-g and the lower 3 wells were not. The bound immunoglobu
antibody. (B) Inhibition binding activity of anti-IFN-g autoantibody was as described in the “C
with pTb and pNTM, and normal controls except the 1st lane from the left. The sample of the
used for the antigen capture assays. The vertical axis is absorption of IFN-g, as shown by opti
blood mononuclear cells (PBMNCs) were measured using sera from a normal individual, as
complete medium (RPMI1640 and 10%/v fetal calf serum) were incubated with LPS (200 ng/m
as sera from other previous pNTM patients and normal controls. All added sera were the s3. Discussion
Disseminated NTM disease usually occurs in patients who are
severely immunocompromised, such as those with HIV disease or
AIDS. However, some dNTM disease cases do not have HIV infec-
tion. There are two retrospective clinical analyses of dNTM disease
without HIV infection.7,8 Chou et al. reported that their 18 patients
without HIV infection were usually febrile with elevated WBC
counts.7 NTM was mainly isolated from not only the lung but also
blood or bone marrow, and MAC was the most frequently detected
pathogen in their study.7 Chetchotisakd et al. reported that NTM
was most frequently detected in lymph nodes in their 129 dNTM
patients without HIV infection.8 It is noteworthy that in both of
these studies, dNTM patients had other opportunistic or severe
infections in addition to the NTM. These included Salmonellosis,
severe systemic intravascular infection, fungal infections including
Aspergillus spp, Candida spp and Penicillium marneffei, and viral
infections including varicella zoster and cytomegalovirus.
Furthermore, the cases with dNTM disease, conﬁrmed by detection
of NTM in multiple specimens, often did not have HIV. With
adequate anti-AFB treatment, the survival rate was better than
without such treatment. Female gender and co-infectionwith other
bacterial pathogens were associated with poor outcomes. However,
HIV infection had no signiﬁcant prognostic impact.
In 2005, two important studies detected autoantibodies against
IFN-g in plasma from dNTMpatients without HIV infection.4,5 IFN-g
has a crucial role in the control and regulation of NTM disease
because some mutations in the genes for Th1 cytokines and their(left lane), a pulmonary tuberculosis (pTb) patient’s serum (2nd lane from the left),
) sera (4the6th lanes from the left). In each lane, the upper 3 wells were coated with
lins were detected using horseradish peroxidase conjugated anti-human Fab speciﬁc
ase report” section. All samples include 100 pg of IFN-g and sera from patients, patients
1st lane contained 100 pg of IFN-g only with PBS. All added sera were the same as those
cal density at 450 nm (OD450). (C) and (D) Productions of TNF-a and IL-10 by peripheral
described in the “Case report” section. In total, 1.0  106 PBMNCs in a total of 2 mL of
l) and IFN-g (1 ng/ml) in the presence of 100 ml of our present patient’s serum, as well
ame as those used for the antigen capture assays.
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reported that anti-IFN-g autoantibody is detected even in sera from
healthy individuals.10 However, the reason for the existence of an
autoantibody against IFN-g remains unclear. Evaluating anti-IFN-g
autoantibody in healthy individuals is important for elucidating the
autoantibody differences between dNTM patients and healthy
individuals. There must be an underlying factor triggering the onset
of dNTM disease in the absence of HIV-infection.
Regarding these previous reports, we considered it to be
important for understanding the present patient’s pathophysiology
to assay his serum. We wanted to know whether his serum con-
tained speciﬁc immunoglobulins which bound and neutralized IFN-
g. To assay anti-IFN-g autoantibody, we applied a protocol allowing
comparison with bioassay results obtained using normal PBMNCs,
as described in previous reports.5 In our view, mediastinal
lymphadenopathy with elevated WBC counts and leukocytosis, of
unknown origin, should prompt assay of the patient’s serum to
detect anti-IFN-g autoantibody. In addition, we suggest that
infectious organisms such as P. marneffei, which are rare in
immunocompetent patients without HIV infection, should be
cultured along with conducting the anti-IFN-g autoantibody assay.
Our present case showed no speciﬁc signs or symptoms pointing
to an accurate diagnosis. His noteworthy signs were elevated WBC
counts, mediastinal lymphadenopathy and general malaise.
According to previous reports, symptoms in the present case might
support a diagnosis of dNTM disease without HIV infection.
On the other hand, this patient was ﬁrst suspected to have MCD,
and was treated with tocilizumab, a monoclonal antibody against
the human interleukin-6 receptor (IL-6R). However, after tocilizu-
mab administration, his serum IL-6 level (normal range: <4.0 pg/
ml) increased from 108 pg/ml to 12,987 pg/ml (the 44th hospital
day). We thus considered tocilizumab administration to have had
no inﬂuence on his deteriorating state.
No standard control for anti-IFN-g autoantibody detection is yet
available. Although dNTM disease with anti-IFN-g autoantibody is
still rare, the relationships between the quantity and neutralizing
capacity of anti-IFN-g autoantibody and disease development
warrant evaluation in the near future. Whether anti-IFN-g auto-
antibody is monoclonal or polyclonal is another important issue in
dNTM disease cases without HIV infection.
In conclusion, we have reported herein a case of dNTM caused by
M. kansasiiwith anti-IFN-g autoantibody. In our view, patients who
have dNTM disease without HIV infection should be evaluated for
the presence of anti-IFN-g autoantibody. In addition, we advocate
that anti-IFN-g autoantibody be measured in non-HIV patients.
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